Chronic immune diseases

Allergy

• Omalizumab

  • Adjunct Therapy to Multi-Allergen OIT in Food Allergic Patients.

Bowel diseases

• Adalimumab

  • Humira is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.

• Alicaforsen

  • Ulcerative colitis
  • Pouchitis
• Apraglutide

• Budesonide

  • Proctitis Ulcerosa (mild matig)
• Darvadstrocel

• Etrasimod

  • Velsipity is geïndiceerd voor de behandeling van patiënten van 16 jaar en ouder met matig tot ernstig actieve colitis ulcerosa (CU) die onvoldoende reageren of niet meer reageren op of intolerant zijn voor conventionele behandeling of een biologisch middel.
  • Velsipity is geïndiceerd voor de behandeling van patiënten van 16 jaar en ouder met matig tot ernstig actieve colitis ulcerosa (CU) die onvoldoende reageren of niet meer reageren op of intolerant zijn voor conventionele behandeling of een biologisch middel.

• Etrolizumab

  • Moderately to severely active Crohn's disease
  • Ulcerative colitis

• Filgotinib

  • Extension of indication to include the treatment of active ulcerative colitis in adults patients for Jyseleca.
  • Crohn disease (bowel disease) Moderately to Severe
• Glepaglutide

• Guselkumab

  • Tremfya is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biologic treatment.
  • Tremfya is indicated for the treatment of adult patients with moderately to severely active Crohnʼs disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic treatment.

• Hydrocortison

  • Hydrocortisone monotherapy for treatment of active rectum Ulcerative colitis in adults and elderly.
• Ivarmacitinib

• Masitinib

  • Ziekte van Crohn

• Mirikizumab

  • Omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment
  • Omvoh is indicated for the treatment of adult patients with moderately to severely active Crohnʼs disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.
• Obefazimod

• Ozanimod

  • Extension of indication to include the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

• Remestemcel-L

  • Ziekte van Crohn
• Rifaximin

• Risankizumab

  • Skyrizi is geïndiceerd voor de behandeling van volwassen patiënten met matig tot ernstig actieve ziekte van Crohn die onvoldoende hebben gereageerd op, niet meer reageren op of intolerant waren voor conventionele behandeling of een biologische behandeling.
  • Skyrizi is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

• Teduglutide

  • Treatment of Short Bowel Syndrome.
  • Revestive is indicated for the treatment of patients 4 months corrected gestational age 1 year and above with Short Bowel Syndrome (SBS). Patients should be stable folllowing a period of intestinal adaptation after surgery.

• Tenapanor

  • Irritable bowel syndrome with constipation

• Tofacitinib

  • Tofacitinib is geïndiceerd voor de behandeling van matig tot ernstig actieve colitis ulcerosa (CU) bij volwassen patiënten die onvoldoende reageerden op, niet meer reageerden op of intolerant waren voor ofwel conventionele behandeling ofwel voor een biologisch middel

• Upadacitinib

  • RINVOQ is geïndiceerd voor de behandeling van volwassen patiënten met matige tot ernstige actieve ziekte van Crohn die onvoldoende reageerden op, niet meer reageerden op of intolerant waren voor een conventionele behandeling of een biologisch geneesmiddel (‘biological’).
  • Rinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

• Ustekinumab

  • Moderately to severely active Ulcerative Colitis
  • Stelara is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.
  • STELARA is indicated for the treatment of moderately to severely active Crohn’s disease in paediatric patients weighing at least 40 kg, who have had an inadequate response to, or were intolerant to either conventional or biologic therapy.
  • Extension of indication to include treatment of moderately to severely active Crohnʼs disease in paediatric patients from the age of 2 years and older, who have had an inadequate response to, or were intolerant to either conventional or biologic therapy.
• Vedolizumab ^IND

Cardiovascular diseases

• Rituximab

  • MabThera, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥2 to <18 years old) with severe, active GPA (Wegener’s) and MPA.
  • MabThera, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).

• Secukinumab

  • Secukinumab in combination with glucocorticoid taper regimen for treatment of giant cell arteritis in adults over 50 and elderly.

• Tocilizumab

  • Treatment of adult giant cell arteritis.

Eye disorders

• Adalimumab

  • Humira is bestemd voor de behandeling van juveniele chronische niet-infectieuze uveitis anterior bij patiënten vanaf twee jaar die een ontoereikende respons hebben gehad op conventionele behandeling of deze niet verdragen, of voor wie conventionele behandeling niet geschikt is.
• Fluocinolone acetonide ^IND
• Veligrotug

Other chronic immune diseases

• 13-grass pollen extract

• Abatacept

  • Primary Sjögren's Syndrome
• Adrenaline
• Allergeenextract huisstofmijt ^IND

• Anakinra

  • Kineret is indicated for the treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate.

• Apremilast

  • Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s disease (BD) who are candidates for systemic therapy.
• Arachis hypogaea (pinda) allergenen ^IND
• Arachis hypogaea (pinda) allergenen (capsule)
• Arachis hypogaea (pinda) allergenen (pleister)
• Atrasentan
• Avacopan

• Avapritinib

  • Extension of indication to include treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment.

• Baricitinib

  • Uitbreiding indicatie met de behandeling van ernstige alopecia areata bij volwassen patiënten
  • Systemic lupus erythematosus
  • Extension of indication to include treatment of adolescent patients (12 to less than 18 years) with severe alopecia areata.
• Belatacept ^IND

• Belimumab

  • Benlysta is indicated as add-on therapy in patients aged 5 years and older with active, autoantibody- positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti dsDNA and low complement) despite standard therapy.
  • Benlysta is indicated as add-on therapy in patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti-dsDNA and low complement) despite standard therapy (see section 5.1).
  • Benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.

• Benralizumab

  • Bulleus pemfigoïd

• Berotralstat

  • Orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.
  • Berotralstat monotherapy for prophylactic treatment of hereditary angioedema in children aged 2 to 12.
• Briquilimab

• Budesonide

  • Geïndiceerd voor de behandeling van eosinofiele oesofagitis (EoE) bij volwassenen (ouder dan 18 jaar)
  • Kinpeygo is indicated for the treatment of adults with a urine protein excretion-to-creatinine ratio (UPCR) ≥1,0g/dayg (or urine protein-to-creatinine ratio ≥0,8g/g).
• Budesonide modified released capsule

• Canakinumab

  • Syndroom van Schnitzler
• Coacillium topical
• Deucrictibant
• Donidalorsen

• Dupilumab

  • Dupixent is geïndiceerd voor de behandeling van eosinofiele oesofagitis in volwassenen, adolescenten en kinderen van een jaar en ouder. Die ongecontroleerd zijn op, intolerant zijn voor, of die geen kandidaat zijn voor conventionele therapie.
  • Dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.
• Elobixibat

• Emapalumab

  • Gamifant is indicated for the treatment of pediatric patients aged under 18 years with primary haemophagocytic lymphohistiocytosis (pHLH).
• Epinephrine
• FCR 001
• Forigerimod
• Garadacimab
• Ianalumab

• Icatibant

  • Acute aanvallen van erfelijk angio-oedeem (HAE) bij volwassenen en kinderen vanaf 2 jaar met C1-esteraseremmerdeficiëntie.
  • Voor de behandeling van de symptomen van aanvallen van erfelijk angio-oedeem bij jongeren en kinderen ouder dan twee jaar.

• Imlifidase

  • Idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. The use of Idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.
  • Imlifidase in combination with standard of care for treatment of severe anti-glomerular basement membrane disease in adults and elderly.

• Iptacopan

  • Fabhalta is indicated for the treatment of adult patients with complement 3 glomerulopathy (C3G) in combination with a renin-angiotensin system (RAS) inhibitor, or in patients who are RAS-inhibitor intolerant, or for whom a RAS inhibitor is contraindicated.

• Lanadelumab

  • TAKHZYRO is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 2 years and older.
  • Takhzyro is geïndiceerd voor de routinematige preventie van terugkerende aanvallen van hereditair angio-oedeem (HAE) bij patiënten van 12 jaar en ouder.

• Leniolisib

  • Behandeling van Geactiveerd PI3 Kinase Delta-Syndroom (APDS) bij volwassenen en adolescenten van twaalf jaar en ouder.
  • Leniolisib monotherapy for treatment of Activated PI3 kinase delta syndrome in infants, toddlers and children between 1 to 12 years of age.
• Lesinurad / allopurinol
• Lonvoguran ziclumeran
• Lorecivivint
• Marnetegragene autotemcel

• Masitinib

  • Masitinib in combination with best supportive care for third line or later treatment of severe Indolent systemic mastocytosis and of for the treatment of severe smouldering Systemic mastocytosis i in adults and elderly who are unresponsive to optimal symptomatic treatment.
• Mavorixafor
• Mycofenolaatmofetil ^IND
• Naldemedine

• Obinutuzumab

  • Gazyvaro in combination with mycophenolate mofetil (MMF), is indicated for the treatment of adult patients with active Class III or IV, with or without concomitant Class V, lupus nephritis (LN)

• Pegcetacoplan

  • Extension of indication to include treatment of adults and adolescents aged 12 to 17 years with C3 glomerulopathy or primary immune complex membranoproliferative glomerulopathy.

• Ritlecitinib

  • Litfulo is geïndiceerd voor de behandeling van ernstige alopecia areata bij volwassenen en adolescenten van 12 jaar en ouder.

• Sarilumab

  • Kevzara is indicated for the treatment of polymyalgia rheumatica (PMR) in adult patients who have had an inadequate response to corticosteroids or who experience a relapse during corticosteroid taper.
• Sebetralstat
• Secukinumab-bthr ^BS
• Sibeprenlimab
• Sizavaleucel
• Sutimlimab
• Tadekinig alfa
• Teprasiran

• Tezepelumab

  • Tezepelumab monotherapy for treatment of Eosinophilic oesophagitis in adolescents, adults and elderly with previously documented standard of care treatment.

• Tocilizumab

  • Voor de behandeling van ernstige of levensbedreigende cytokine-release syndrome (CRS) geïnduceerd door chimerische antigeenreceptor (CAR) T-cellen bij volwassenen en kinderen van 2 jaar en ouder.
  • Extension of indication to include treatment of new indication for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) for RoActemra.
• Triamcinolone

• Upadacitinib

  • Moderate to severe Hidradenitis suppurativa in adolescents, adults and elderly who have failed to respond to or are intolerant of anti-tumor necrosis factor (TNF) therapy.
  • Severe Alopecia areata in adolescents and adults.
• Voclosporin

• Vonoprazan

  • Patients with Non-Erosive Gastroesophageal Reflux Disease (NERD)

Rheumatism

• Abatacept

  • Orencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (pJIA) in paediatric patients 2 - 6 years of age who have had an inadequate response to previous DMARD therapy. Orencia can be given as monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate.

• Adalimumab

  • RA, polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis

• Anifrolumab

  • Saphnelo is geïndiceerd als aanvullende therapie voor de behandeling van volwassen patiënten met matige tot ernstige, actieve auto-antilichaampositieve systemische lupus erythematosus (SLE), ondanks standaardbehandeling.
  • Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus (SubQ Tulip).

• Baricitinib

  • Extension of indication to include treatment, as monotherapy or in combination with conventional synthetic disease modifying antirheumatic drugs (DMARDs), of active juvenile idiopathic arthritis (JIA) in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic DMARDs.

• Bimekizumab

  • Bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs), and for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.
  • Bimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).
• Cyclobenzaprine hydrochloride
• Dapansutrile

• Deucravacitinib

  • Sotyktu, alone or in combination with conventional synthetic disease modifying antirheumatic drugs (DMARDs), is indicated for the treatment of active psoriatic arthritis (PsA) in adults who have had an inadequate response or who have been intolerant to a prior DMARD therapy.

• Emapalumab

  • Emapalumab monotherapy for treatment of glucocorticoid-refractory Macrophage activation syndrome in infants, toddlers over 6 months of age, children, adolescents, adults and elderly with Stillʼs Disease.

• Filgotinib

  • Jyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Jyseleca may be used as monotherapy or in combination with methotrexate (MTX).
  • Axial spondyloarthritis
• Golimumab ^BS

• Guselkumab

  • Addition of a new indication for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior Disease-Modifying Antirheumatic Drug (DMARD) therapy.

• Inebilizumab

  • Uplizna is indicated for the treatment of adult patients with active IgG4-RD (see section 5.1).
• Infliximab SC

• Ixekizumab

  • Taltz is indicated for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy and patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).
  • Alleen of in combinatie met methotrexaat geïndiceerd voor de behandeling van actieve artritis psoriatica bij volwassen patiënten die één of meer therapieën met disease-modifying antirheumatic drugs (DMARDs) niet verdroegen of daar ontoereikend op reageerden.
  • Juvenile idiopathic arthritis (JIA). Juvenile psoriatic arthritis (JPsA): Taltz, alone or in combination with methotrexate, is indicated for the treatment of active JPsA in patients 6 years of age and older and with a body weight of at least 25 kg, who have had an inadequate response to, or who are intolerant of, conventional therapy. Enthesitis-related arthritis (ERA): Taltz, alone or in combination with methotrexate, is indicated for the treatment of active ERA in patients 6 years of age and older and with a body weight of at least 25 kg, who have had an inadequate response to, or who are intolerant of, conventional therapy.
• Lingolinurad
• Litifilimab
• Olokizumab

• Risankizumab

  • Skyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).

• Sarilumab

  • Kevzara is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA; rheumatoid factor positive or negative polyarthritis and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with conventional synthetic DMARDs (csDMARDs). Kevzara may be used as monotherapy or in combination with MTX.

• Secukinumab

  • Extension of indication to include polymyalgia rheumatica in adults whose disease has responded inadequately to, or cannot tolerate conventional therapy.
  • Cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).
  • Extension of indication to include treatment of Juvenile Idiopathic Arthritis (Enthesitis Related Arthritis and Juvenile Psoriatic Arthritis) in patients 2 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.
  • Extension of indication to include treatment of Juvenile Idiopathic Arthritis (Enthesitis Related Arthritis and Juvenile Psoriatic Arthritis) in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.
• Sirukumab

• Tildrakizumab

  • Tildrakizumab monotherapy for treatment of active psoriatic arthritis in adults and elderly who have prior or no prior exposure to an anti-tumor necrosis factor agent.

• Tocilizumab

  • Rheumatoid arthritis (RA), giant lymph node hyperplasia (Castlesman’s disease), polyarticular idioathic juvenile arthritis (PJIA) and systemic juvenile idiopathic arthritis (SJIA).
  • RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 1 year of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.

• Tofacitinib

  • Extension of indication for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy.
  • Indicated in combination with MTX for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy.
  • Tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive or negative polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in patients 2 years of age and older, who have responded inadequately to previous therapy with DMARDs. Tofacitinib can be given in combination with methotrexate (MTX) or as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.

• Upadacitinib

  • Rinvoq is indicated for the treatment of giant cell arteritis in adult patients.
  • Rinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. Rinvoq may be used as monotherapy or in combination with methotrexate.
  • Rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.
  • Rinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Rinvoq may be used as monotherapy or in combination with methotrexate.
  • RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).
  • Extension of indication to include the treatment of active polyarticular course juvenile idiopathic arthritis (pcJIA) in patients 2 years of age and older

• Ustekinumab

  • Matig tot ernstige systemische lupus erythematodes (SLE).

Skin diseases

• Abatacept

  • Artritis psoriatica (artritis gecombineerd met psoriasis, een aandoening die rode, schilferige plekken op de huid veroorzaakt) bij volwassenen bij wie behandeling met andere geneesmiddelen, waaronder methotrexaat, niet goed genoeg heeft gewerkt. Het wordt alleen of in combinatie met methotrexaat gebruikt voor patiënten die geen andere via de mond of injectie toegediende geneesmiddelen nodig hebben om hun psoriasis onder controle te houden.

• Abrocitinib

  • Extension of indication to include treatment of adolescents 12 to < 18 years of age with moderate to severe atopic dermatitis
  • Cibinqo is geïndiceerd voor de behandeling van matige tot ernstige atopische dermatitis bij volwassenen die in aanmerking komen voor systemische behandeling.
  • Abrocitinib is geïndiceerd voor de behandeling van matige tot ernstige atopische dermatitis bij adolescenten vanaf 12 jaar tot en met 17 jaar welke in aanmerking komen voor systemische therapie.

• Adalimumab

  • RA, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, pediatric plaque psoriasis, adult and adolescent hidradenitis suppurativa, Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis, uveitis

• Afamelanotide

  • Afamelanotide in combination with Narrow-Band Ultraviolet B (NB-UVB) light for treatment of stable or active generalized Vitiligo in adolescents, adults and elderly.

• Apremilast

  • Extension of indication to include the treatment of moderate to severe chronic plaque psoriasis in children and adolescents from the age of 6 years who have a contraindication, have an inadequate response, or are intolerant to at least one other systemic therapy or phototherap.

• Baricitinib

  • Baricitinib is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years and older who are candidates for systemic therapy.
  • Olumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.
  • Psoriasis (wg); Conditioneel exzeem (wg); Graft vs Host Disease (clinicaltrials.gov); Arteritis, Giant Cell (clinicaltrials.gov)
• Beremagene geperpavec
• Berkenschorsextract

• Bimekizumab

  • Bimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
  • Extension of indication to include treatment of moderate to severe hidradenitis suppurativa (HS) in adults.
• Certolizumab pegol ^IND
• Clascoterone
• Concentrate of proteolytic enzymes enriched in bromelain ^IND
• Crisaborole
• Dabocemagene autoficel
• Delgocitinib

• Deucravacitinib

  • Sotyktu is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
• Deuruxolitinib
• Difelikefalin
• Dipalmitoyl Hydroxyproline

• Dupilumab

  • Extension of indication to include treatment of severe atopic dermatitis in paediatric patients from 6 months to <6 years of age.
  • Dupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults patients and adolescents 12 years and older who are candidates for systemic therapy.
  • Severe atopic dermatitis in children 6 to 11 years old who are candidates for systemic therapy.
  • Dupixent is geïndiceerd voor de behandeling van matig-ernstige tot ernstige atopische dermatitis bij volwassenen die in aanmerking komen voor een systemische behandeling.
  • Extension of indication to include treatment of moderate to severe chronic spontaneous urticaria in adults and adolescents 12 years and older, whose disease is inadequately controlled by H1 antihistamines and who are naive to anti-IgE therapy for CSU.
  • Dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy.
  • Dupixent is geindiceerd voor de behandeling van volwassenen met matig-ernstig bulleus pemfigoid (BP).
  • Extension of indication to include treatment of moderate to severe chronic spontaneous urticaria (CSU) in children aged 2 to 11 years whose disease is inadequately controlled by H1 antihistamines and who are naive to anti-IgE therapy for CSU.
• Glycopyrronium tosylate

• Guselkumab

  • Tremfya is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy
  • Tremfya is aangewezen voor de behandeling van matige tot ernstige plaque psoriasis bij volwassenen die in aanmerking komen voor systemische therapie.
• Humane allogene, uit de huid afkomstige ABCB5+ mesenchymale stromale cellen
• Icotrokinra
• Imsidolimab

• Ixekizumab

  • Taltz is indicated for the treatment of moderate to severe plaque psoriasis in children from the age of 6 years and with a body weight of at least 25 kg and adolescents who are candidates for systemic therapy.

• Lebrikizumab

  • Lebrikizumab in combination with topical corticosteroid for treatment of moderate to severe atopic dermatitis in infants, toddlers over 6 months, children and adolescents.
  • Ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40kg who are candidates for systemic therapy.
• Ligelizumab
• Methotrexaat ^IND

• Minocycline

  • Minocycline monotherapy for treatment of moderate to severe inflammatory lesions of Papulopustular rosacea in adults and elderly.
• Nemolizumab

• Omalizumab

  • Chronische Induceerbare Urticaria (CINDU)
• Piclidenoson
• Povorcitinib ^IND
• Prademagene zamikeracel
• Regenerative Skin Tissue
• Remibrutinib

• Risankizumab

  • Extension application to include treatment of paediatric plaque psoriasis (6 to 18 years)
  • Skyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
  • Patients with Atopic Dermatitis 12 Years and older.

• Ritlecitinib

  • Treatment of patients with non-segmental vitiligo

• Rituximab

  • Moderate to severe pemphigus vulgaris (PV)

• Roflumilast topicaal

  • Chronic plaque psoriasis
  • Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age.

• Ruxolitinib (als fosfaat)

  • Opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
  • Volwassenen met matige atopische dermatitis die eerder zijn behandeld met topische corticosteroïden of topische calcineurine remmers of waarbij deze middelen zijn gecontra-indiceerd.

• Secukinumab

  • Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.
  • Extension of indication to include treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy

• Sirolimus

  • Hyftor is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 years and older.

• Spesolimab

  • Spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (GPP) as monotherapy.
  • Spevigo is indicated for the prevention of generalised pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age.

• Tapinarof

  • Adult Plaque Psoriasis
  • Atopische dermatitis

• Tildrakizumab

  • Tildrakizumab monotherapy for treatment of active Psoriatic arthritis in adults and elderly who have no prior exposure to anti-tumor necrosis factor agent.
  • Ilumetri is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.
• Tirbanibulin
• Tirbanibuline ^IND

• Tralokinumab

  • Adtralza is indicated for treatment of moderate‑to‑severe atopic dermatitis in adult patients who are candidates for systemic therapy.
  • Adtralza is indicated for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.
• Trifarotene

• Upadacitinib

  • Non-segmental Vitiligo in adolescents, adults and elderly who are eligible for systemic therapy.
  • Rinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.

• Ustekinumab

  • Stelera is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.
• Zasocitinib

Unknown

• Apremilast

  • Treatment of psoriatic arthritis, psoriasis, Behçet’s disease
• Olopatadine / mometasone

Unknown

• Atacicept